| Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large … DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ... Journal of clinical oncology 27 (34), 5794-5799, 2009 | 2300 | 2009 |
| Renal cell carcinoma JJ Hsieh, MP Purdue, S Signoretti, C Swanton, L Albiges, M Schmidinger, ... Nature reviews Disease primers 3 (1), 1-19, 2017 | 2284 | 2017 |
| Cabozantinib versus everolimus in advanced renal-cell carcinoma TK Choueiri, B Escudier, T Powles, PN Mainwaring, BI Rini, F Donskov, ... New England Journal of Medicine 373 (19), 1814-1823, 2015 | 1273 | 2015 |
| Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial TK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, ... The lancet oncology 17 (7), 917-927, 2016 | 1049 | 2016 |
| External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study DYC Heng, W Xie, MM Regan, LC Harshman, GA Bjarnason, ... The lancet oncology 14 (2), 141-148, 2013 | 1048 | 2013 |
| Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised … RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ... The Lancet Oncology 20 (10), 1370-1385, 2019 | 726 | 2019 |
| Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium DYC Heng, JC Wells, BI Rini, B Beuselinck, JL Lee, JJ Knox, ... European urology 66 (4), 704-710, 2014 | 505 | 2014 |
| Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study HJ Hammers, ER Plimack, JR Infante, BI Rini, DF McDermott, LD Lewis, ... Journal of Clinical Oncology 35 (34), 3851-3858, 2017 | 460 | 2017 |
| The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy TK Choueiri, W Xie, C Kollmannsberger, S North, JJ Knox, JG Lampard, ... The Journal of urology 185 (1), 60-66, 2011 | 432 | 2011 |
| The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first … JJ Ko, W Xie, N Kroeger, J Lee, BI Rini, JJ Knox, GA Bjarnason, S Srinivas, ... The lancet oncology 16 (3), 293-300, 2015 | 366 | 2015 |
| Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). A Amin, ER Plimack, JR Infante, MS Ernstoff, BI Rini, DF McDermott, ... Journal of Clinical Oncology 32 (15_suppl), 5010-5010, 2014 | 291 | 2014 |
| Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor–targeted therapy AR Golshayan, S George, DY Heng, P Elson, LS Wood, TM Mekhail, ... Journal of Clinical Oncology 27 (2), 235-241, 2009 | 269 | 2009 |
| Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy RR McKay, N Kroeger, W Xie, JL Lee, JJ Knox, GA Bjarnason, ... European urology 65 (3), 577-584, 2014 | 255 | 2014 |
| Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database … N Kroeger, W Xie, JL Lee, GA Bjarnason, JJ Knox, MJ MacKenzie, ... Cancer 119 (16), 2999-3006, 2013 | 234 | 2013 |
| Body mass index and metastatic renal cell carcinoma: clinical and biological correlations L Albiges, AA Hakimi, W Xie, RR McKay, R Simantov, X Lin, JL Lee, ... Journal of Clinical Oncology 34 (30), 3655-3663, 2016 | 220 | 2016 |
| Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group J Manola, P Royston, P Elson, JB McCormack, M Mazumdar, S Négrier, ... Clinical Cancer Research 17 (16), 5443-5450, 2011 | 218 | 2011 |
| Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma DJ Kwiatkowski, TK Choueiri, AP Fay, BI Rini, AR Thorner, G De Velasco, ... Clinical Cancer Research 22 (10), 2445-2452, 2016 | 217 | 2016 |
| A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial SK Pal, C Tangen, IM Thompson, N Balzer-Haas, DJ George, DYC Heng, ... The Lancet 397 (10275), 695-703, 2021 | 207 | 2021 |
| Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib CJ Richards, Y Je, FAB Schutz, DYC Heng, SM Dallabrida, JJ Moslehi, ... Journal of clinical oncology 29 (25), 3450-3456, 2011 | 186 | 2011 |
| Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study A Amin, ER Plimack, MS Ernstoff, LD Lewis, TM Bauer, DF McDermott, ... Journal for immunotherapy of cancer 6, 1-12, 2018 | 185 | 2018 |
